Glycomimetics Inc (GLYC) 7.77 $GLYC
GlycoMimetics to Present at 17th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 03, 8:02AM CST
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that Chief Executive Officer Rachel King will provide a company overview at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 3:00 p.m. Eastern Time. The conference will take place at The Waldorf Astoria New York.
GLYC: 7.77 (+0.12)
GlycoMimetics: The $57.2 Million IPO Anniversary
Shelby Cardozo - at Seeking Alpha - Sun Jan 04, 11:55AM CST
PFE: 34.64 (-0.23), GLYC: 7.77 (+0.12)
Venous Thromboembolism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/h48x9c/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Venous Thromboembolism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Venous Thromboembolism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Bayer AG - Portola Pharmaceuticals, Inc. - Green Cross Corporation - Regado Biosciences, Inc. - GlycoMimetics, Inc. - Gamma Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/h48x9c/venous
PTLA: 34.96 (+3.13), ISIS: 63.86 (-0.43), GLYC: 7.77 (+0.12), RGDO: 1.17 (+0.02)
GlycoMimetics Highlights Potential Therapeutic Benefits of Its Novel E-Selectin Antagonist at 56th ASH Annual Meeting
Business Wire - Tue Dec 09, 8:01AM CST
--Biomarker Data from Phase 2 Study of Rivipansel Also Displayed via Poster Session at ASH Meeting
GLYC: 7.77 (+0.12)
University of Michigan to Study GlycoMimetics' GMI-1271 as Potential Treatment for Serious Blood-Clotting Disorder
Business Wire - Thu Dec 04, 8:01AM CST
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the University of Michigan (U-M) has dosed the first healthy volunteer in a Phase 1 clinical trial of GMI-1271, a novel and proprietary E-selectin antagonist. U-M researchers will study use of GMI-1271 in healthy volunteers to evaluate safety and pharmacokinetics (PK), as well as biomarkers of coagulation.
GLYC: 7.77 (+0.12)
GlycoMimetics Announces Positive Top-Line Results from Phase 1 Study of GMI-1271 in Healthy Volunteers
Business Wire - Mon Nov 17, 3:00PM CST
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that healthy volunteers in a Phase 1 clinical study of GMI-1271 tolerated the drug candidate well, and that the pharmacokinetics for the drug candidate were as predicted based on preclinical data. The findings represent positive top-line results from a Phase 1 trial designed to evaluate the safety, tolerability and pharmacokinetics of GMI-1271, the GlycoMimetics-discovered novel and proprietary E-selectin antagonist. Based on these data, GlycoMimetics is planning a Phase 1/2 trial of GMI-1271 as an adjunct to standard chemotherapy in patients with acute myeloid leukemia (AML).
GLYC: 7.77 (+0.12)
GlycoMimetics to Present at Stifel Healthcare Conference 2014
Business Wire - Wed Nov 12, 8:03AM CST
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Financial Officer Brian Hahn will provide a company overview at the Stifel Healthcare Conference 2014 on Tuesday, November 18, 2014 at 3:00 p.m. Eastern Time. The conference will take place in New York City.
GLYC: 7.77 (+0.12)
GlycoMimetics E-selectin and Sickle Cell Data to Be Highlighted at 56th ASH Annual Meeting
Business Wire - Thu Nov 06, 8:33AM CST
--New data for rivipansel, sickle cell investigational drug candidate, show effects on biomarkers
GLYC: 7.77 (+0.12)
GlycoMimetics reports Q3 loss
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 10:41AM CDT
GLYC: 7.77 (+0.12)
GlycoMimetics Reports Third Quarter 2014 Results
Business Wire - Fri Oct 31, 8:15AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the third quarter ended September 30, 2014. As of September 30, 2014, GlycoMimetics had cash and cash equivalents of $61.4 million, which reflects the company's net proceeds of $57.2 million from its January 2014 initial public offering and a $15.0 million non-refundable milestone payment received from Pfizer in May 2014 under the terms of the parties' collaboration agreement for development of rivipansel (previously known as GMI-1070).
GLYC: 7.77 (+0.12)
GlycoMimetics to Present at BIO Investor Forum
GlobeNewswire - Fri Oct 03, 3:00PM CDT
GlycoMimetics, Inc. (Nasdaq:GLYC) today announced that CEO Rachel King will provide a company presentation at the 13th Annual BIO Investor Forum on Tuesday, October 7, 2014 at 1:30 p.m. Eastern Time. Hosted by the Biotechnology Industry Organization (BIO), the Conference will take place October 7-8 at the Palace Hotel in San Francisco.
GLYC: 7.77 (+0.12)
Civeo Rebounds Following Monday's Plunge
at The Street - Wed Oct 01, 12:06PM CDT
With the S&P 500 down -0.71% midday, this Wednesday is starting off slow on Wall Street. A handful of companies, however, are making strong gains. Here's a look at the four top-gaining billionai...
BWC: 29.88 (+0.81), SRPT: 12.76 (+0.11), GLYC: 7.77 (+0.12), CVEO: 3.87 (+0.15)
GlycoMimetics Down Due to Delay in Rivipansel Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 2:10PM CDT
GlycoMimetics Inc. (GLYC) announced that the initiation of a phase III study on rivipansel (to be conducted by its partner Pfizer Inc.) will be delayed indefinitely.
LCI: 57.78 (-0.91), ENDP: 84.01 (+1.12), PFE: 34.64 (-0.23), GLYC: 7.77 (+0.12)
Market Maker Surveillance Report. RITT, GNI, GTI, GLYC, CLVLY, PULS, Losing Stocks With Lowest Price Friction For Friday, September 26th 2014
M2 - Mon Sep 29, 2:48AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4860 companies with "abnormal" market making, 3007 companies with positive Friction Factors and 1840 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Friday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Rit Technologies Ltd (NASDAQ:RITT), Great Northern Iron Ore Properties (NYSE:GNI), Graftech International Ltd (NYSE:GTI), GLYCOMED INC (NASDAQ:GLYC), Clinuvel Pharmaceuticals Ltd (OTC:CLVLY), Pulse Electronics Corp (NYSE
ULS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
GLYC: 7.77 (+0.12), GTI: 4.16 (+0.32), RITT: 1.29 (unch), GNI: 10.94 (+0.15)
GlycoMimetics Announces a Delay in the Initiation of the Phase 3 Trial With Rivipansel
GlobeNewswire - Fri Sep 26, 8:01AM CDT
GlycoMimetics, Inc. (Nasdaq:GLYC) announced today that it has been informed by Pfizer (NYSE FE), the company responsible for ongoing clinical development of rivipansel, that initiation of its Phase 3 clinical trial with rivipansel (GMI-1070) will be significantly delayed due to a manufacturing development issue impacting formulated drug supply. Pfizer advised GlycoMimetics that the issue is under review and Pfizer is working diligently to remedy the situation. Pfizer also noted that upon identifying the specific cause and associated remedy of the manufacturing issue, Pfizer will advise GlycoMimetics of a more specific timeframe regarding the commencement of the Phase 3 study.
PFE: 34.64 (-0.23), GLYC: 7.77 (+0.12)
5 Stocks Under $10 Making Big Moves Higher
at The Street - Wed Sep 24, 6:18AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
PLUG: 3.15 (unch), NPTN: 3.20 (unch), MNDO: 3.34 (+0.01), GLYC: 7.77 (+0.12), NQ: 3.95 (-0.03)
GlycoMimetics to Present at BioCentury's 21st Annual Newsmakers in the Biotech Industry Conference
GlobeNewswire - Mon Sep 22, 8:53AM CDT
GlycoMimetics, Inc. (Nasdaq:GLYC) today announced that Rachel King, Chief Executive Officer, will present an overview of the company at BioCentury's 21 Annual Newsmakers in the Biotech Industry Conference on September 26, 2014, at 9:30 a.m. Eastern Time in New York City.
GLYC: 7.77 (+0.12)
5 Stocks Under $10 to Trade for Breakouts
at The Street - Thu Sep 18, 6:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
NLST: 1.86 (unch), ANY: 3.52 (+0.05), OGXI: 2.06 (-0.05), GLYC: 7.77 (+0.12)
Data on GlycoMimetics' Drug Candidate's Potential to Treat Lung Infections Caused by Pseudomonas Aeruginosa to Be Presented at North American Cystic Fibrosis Conference
GlobeNewswire - Mon Sep 08, 3:16PM CDT
GlycoMimetics, Inc. (Nasdaq:GLYC) announced today that data from preclinical studies demonstrating the in vivo efficacy of GMI-1051, a drug candidate being developed to treat or prevent infections caused by Pseudomonas aeruginosa, will be presented at the 28 Annual North American Cystic Fibrosis Conference (NACFC). The conference will be held October 9-11, 2014 at the Georgia World Congress Center in Atlanta, GA.
GLYC: 7.77 (+0.12)
BioMed Realty Inks Lease Agreement with GlycoMimetics in MD - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 4:20PM CDT
BioMed Realty Trust, Inc. (BMR) inked a new deal with GlycoMimetics, Inc. (GLYC) for leasing a property at the Center for Life Science | Shady Grove in Rockville, MD.
BMR: 22.85 (-0.13), PFE: 34.64 (-0.23), GLYC: 7.77 (+0.12), NHI: 71.74 (-0.24)
GlycoMimetics to Present at 17th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 03, 8:02AM CST
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that Chief Executive Officer Rachel King will provide a company overview at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 3:00 p.m. Eastern Time. The conference will take place at The Waldorf Astoria New York.
GLYC: 7.77 (+0.12)
GlycoMimetics: The $57.2 Million IPO Anniversary
Shelby Cardozo - at Seeking Alpha - Sun Jan 04, 11:55AM CST
PFE: 34.64 (-0.23), GLYC: 7.77 (+0.12)
Venous Thromboembolism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/h48x9c/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Venous Thromboembolism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Venous Thromboembolism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Bayer AG - Portola Pharmaceuticals, Inc. - Green Cross Corporation - Regado Biosciences, Inc. - GlycoMimetics, Inc. - Gamma Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/h48x9c/venous
PTLA: 34.96 (+3.13), ISIS: 63.86 (-0.43), GLYC: 7.77 (+0.12), RGDO: 1.17 (+0.02)
GlycoMimetics Highlights Potential Therapeutic Benefits of Its Novel E-Selectin Antagonist at 56th ASH Annual Meeting
Business Wire - Tue Dec 09, 8:01AM CST
--Biomarker Data from Phase 2 Study of Rivipansel Also Displayed via Poster Session at ASH Meeting
GLYC: 7.77 (+0.12)
University of Michigan to Study GlycoMimetics' GMI-1271 as Potential Treatment for Serious Blood-Clotting Disorder
Business Wire - Thu Dec 04, 8:01AM CST
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the University of Michigan (U-M) has dosed the first healthy volunteer in a Phase 1 clinical trial of GMI-1271, a novel and proprietary E-selectin antagonist. U-M researchers will study use of GMI-1271 in healthy volunteers to evaluate safety and pharmacokinetics (PK), as well as biomarkers of coagulation.
GLYC: 7.77 (+0.12)
GlycoMimetics Announces Positive Top-Line Results from Phase 1 Study of GMI-1271 in Healthy Volunteers
Business Wire - Mon Nov 17, 3:00PM CST
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that healthy volunteers in a Phase 1 clinical study of GMI-1271 tolerated the drug candidate well, and that the pharmacokinetics for the drug candidate were as predicted based on preclinical data. The findings represent positive top-line results from a Phase 1 trial designed to evaluate the safety, tolerability and pharmacokinetics of GMI-1271, the GlycoMimetics-discovered novel and proprietary E-selectin antagonist. Based on these data, GlycoMimetics is planning a Phase 1/2 trial of GMI-1271 as an adjunct to standard chemotherapy in patients with acute myeloid leukemia (AML).
GLYC: 7.77 (+0.12)
GlycoMimetics to Present at Stifel Healthcare Conference 2014
Business Wire - Wed Nov 12, 8:03AM CST
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Financial Officer Brian Hahn will provide a company overview at the Stifel Healthcare Conference 2014 on Tuesday, November 18, 2014 at 3:00 p.m. Eastern Time. The conference will take place in New York City.
GLYC: 7.77 (+0.12)
GlycoMimetics E-selectin and Sickle Cell Data to Be Highlighted at 56th ASH Annual Meeting
Business Wire - Thu Nov 06, 8:33AM CST
--New data for rivipansel, sickle cell investigational drug candidate, show effects on biomarkers
GLYC: 7.77 (+0.12)
GlycoMimetics reports Q3 loss
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 10:41AM CDT
GLYC: 7.77 (+0.12)
GlycoMimetics Reports Third Quarter 2014 Results
Business Wire - Fri Oct 31, 8:15AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the third quarter ended September 30, 2014. As of September 30, 2014, GlycoMimetics had cash and cash equivalents of $61.4 million, which reflects the company's net proceeds of $57.2 million from its January 2014 initial public offering and a $15.0 million non-refundable milestone payment received from Pfizer in May 2014 under the terms of the parties' collaboration agreement for development of rivipansel (previously known as GMI-1070).
GLYC: 7.77 (+0.12)
GlycoMimetics to Present at BIO Investor Forum
GlobeNewswire - Fri Oct 03, 3:00PM CDT
GlycoMimetics, Inc. (Nasdaq:GLYC) today announced that CEO Rachel King will provide a company presentation at the 13th Annual BIO Investor Forum on Tuesday, October 7, 2014 at 1:30 p.m. Eastern Time. Hosted by the Biotechnology Industry Organization (BIO), the Conference will take place October 7-8 at the Palace Hotel in San Francisco.
GLYC: 7.77 (+0.12)
Civeo Rebounds Following Monday's Plunge
at The Street - Wed Oct 01, 12:06PM CDT
With the S&P 500 down -0.71% midday, this Wednesday is starting off slow on Wall Street. A handful of companies, however, are making strong gains. Here's a look at the four top-gaining billionai...
BWC: 29.88 (+0.81), SRPT: 12.76 (+0.11), GLYC: 7.77 (+0.12), CVEO: 3.87 (+0.15)
GlycoMimetics Down Due to Delay in Rivipansel Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 2:10PM CDT
GlycoMimetics Inc. (GLYC) announced that the initiation of a phase III study on rivipansel (to be conducted by its partner Pfizer Inc.) will be delayed indefinitely.
LCI: 57.78 (-0.91), ENDP: 84.01 (+1.12), PFE: 34.64 (-0.23), GLYC: 7.77 (+0.12)
Market Maker Surveillance Report. RITT, GNI, GTI, GLYC, CLVLY, PULS, Losing Stocks With Lowest Price Friction For Friday, September 26th 2014
M2 - Mon Sep 29, 2:48AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4860 companies with "abnormal" market making, 3007 companies with positive Friction Factors and 1840 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Friday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Rit Technologies Ltd (NASDAQ:RITT), Great Northern Iron Ore Properties (NYSE:GNI), Graftech International Ltd (NYSE:GTI), GLYCOMED INC (NASDAQ:GLYC), Clinuvel Pharmaceuticals Ltd (OTC:CLVLY), Pulse Electronics Corp (NYSE
ULS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . GLYC: 7.77 (+0.12), GTI: 4.16 (+0.32), RITT: 1.29 (unch), GNI: 10.94 (+0.15)
GlycoMimetics Announces a Delay in the Initiation of the Phase 3 Trial With Rivipansel
GlobeNewswire - Fri Sep 26, 8:01AM CDT
GlycoMimetics, Inc. (Nasdaq:GLYC) announced today that it has been informed by Pfizer (NYSE
FE), the company responsible for ongoing clinical development of rivipansel, that initiation of its Phase 3 clinical trial with rivipansel (GMI-1070) will be significantly delayed due to a manufacturing development issue impacting formulated drug supply. Pfizer advised GlycoMimetics that the issue is under review and Pfizer is working diligently to remedy the situation. Pfizer also noted that upon identifying the specific cause and associated remedy of the manufacturing issue, Pfizer will advise GlycoMimetics of a more specific timeframe regarding the commencement of the Phase 3 study. PFE: 34.64 (-0.23), GLYC: 7.77 (+0.12)
5 Stocks Under $10 Making Big Moves Higher
at The Street - Wed Sep 24, 6:18AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
PLUG: 3.15 (unch), NPTN: 3.20 (unch), MNDO: 3.34 (+0.01), GLYC: 7.77 (+0.12), NQ: 3.95 (-0.03)
GlycoMimetics to Present at BioCentury's 21st Annual Newsmakers in the Biotech Industry Conference
GlobeNewswire - Mon Sep 22, 8:53AM CDT
GlycoMimetics, Inc. (Nasdaq:GLYC) today announced that Rachel King, Chief Executive Officer, will present an overview of the company at BioCentury's 21 Annual Newsmakers in the Biotech Industry Conference on September 26, 2014, at 9:30 a.m. Eastern Time in New York City.
GLYC: 7.77 (+0.12)
5 Stocks Under $10 to Trade for Breakouts
at The Street - Thu Sep 18, 6:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
NLST: 1.86 (unch), ANY: 3.52 (+0.05), OGXI: 2.06 (-0.05), GLYC: 7.77 (+0.12)
Data on GlycoMimetics' Drug Candidate's Potential to Treat Lung Infections Caused by Pseudomonas Aeruginosa to Be Presented at North American Cystic Fibrosis Conference
GlobeNewswire - Mon Sep 08, 3:16PM CDT
GlycoMimetics, Inc. (Nasdaq:GLYC) announced today that data from preclinical studies demonstrating the in vivo efficacy of GMI-1051, a drug candidate being developed to treat or prevent infections caused by Pseudomonas aeruginosa, will be presented at the 28 Annual North American Cystic Fibrosis Conference (NACFC). The conference will be held October 9-11, 2014 at the Georgia World Congress Center in Atlanta, GA.
GLYC: 7.77 (+0.12)
BioMed Realty Inks Lease Agreement with GlycoMimetics in MD - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 4:20PM CDT
BioMed Realty Trust, Inc. (BMR) inked a new deal with GlycoMimetics, Inc. (GLYC) for leasing a property at the Center for Life Science | Shady Grove in Rockville, MD.
BMR: 22.85 (-0.13), PFE: 34.64 (-0.23), GLYC: 7.77 (+0.12), NHI: 71.74 (-0.24)
